thalidomide

(redirected from Thalomid)
Also found in: Dictionary, Thesaurus, Medical.

thalidomide

(thəlĭd`əmĭd'), sleep-inducing drug found to produce skeletal defects in developing fetuses. The drug was marketed in Europe, especially in West Germany and Britain, from 1957 to 1961, and was thought to be so safe that it was sold without prescription. In 1961 an extremely high incidence of European babies born with malformed, shortened limbs was correlated with use of thalidomide by women in their first trimester of pregnancy. Before it was recalled from use the drug had caused the malformation of about 8,000 children throughout the world.

Thalidomide never entirely disappeared from use, however, and it was later found to benefit some leprosyleprosy
or Hansen's disease
, chronic, mildly infectious malady capable of producing, when untreated, various deformities and disfigurements. It is caused by the rod-shaped bacterium Mycobacterium leprae, first described by G.
..... Click the link for more information.
 patients. In 1998, after a complex safety monitoring system had been established to prevent further birth defects, thalidomide was approved for use in the United States for a complication of leprosy. The drug is also used to treat multiple myeloma, a cancer that affects the bone marrow.

thalidomide

[thə′lid·ə‚mīd]
(pharmacology)
C13H10N2O4 A drug used as a sedative and hypnotic; may produce teratogenic effects when administered during pregnancy.

thalidomide

supposedly harmless sedative resulted in disfigured babies. [Am. Hist.: Van Doren, 582–583]

thalidomide

a. a synthetic drug formerly used as a sedative and hypnotic but withdrawn from the market when found to cause abnormalities in developing fetuses. Formula: C13H10N2O4
b. (as modifier): a thalidomide baby
References in periodicals archive ?
As mandated by the US Food and Drug Administration, Thalomid is subject to Risk Evaluation and Mitigation Strategies program, which is designed and implemented during the commercialisation of a pharmaceutical product to ensure an acceptable risk-to-benefit ratio for products that are known to exhibit specific risks.
He presented an update of a study that was sponsored by Celgene Corp., the maker of Thalomid. The trial involved 180 patients who were treated with thalidomide starting at a dosage of 200 mg/day and escalating to a maximum dosage of 800 mg/day every 2 weeks as tolerated.
Celgene promoted Thalomid for the treatment of multiple myeloma before its approval in May 2006.
The litigation was mainly regarding allegations that the company promoted Thalomid (thalidomide) for off-label uses before its 2006 FDA approval for newly diagnosed multiple myeloma.
Celgene Corp., which involves allegations that Celgene has prevented Mylan from offering competing generic versions of Celgene's brand drug products, Thalomid and Revlimid, by precluding them from obtaining samples of those drugs to perform necessary testing.
In 2009, the drugs Gleevec (imatinib mesylate), Sutent (sunitinib malate), Tarceva (erlotinib), Thalomid (thalidomide), and Tykerb (lapatinib) will all be placed on a top formulary tier, with beneficiaries having to pay 26%-35% of the drugs' cost.
Celgene would gain Vidaza, a treatment for blood cancer, as part of the deal, boosting its own pipeline of products, which include Revlimid and Thalomid. Revlimid is a direct competitor to Vidaza.
The safety and effectiveness of Kyprolis, which is administered directly into a patient s vein (intravenously), was evaluated in a study of 266 patients with relapsed multiple myeloma who had received at least two prior therapies, including Velcade and Thalomid (thalidomide).
* There are many examples of repositioned drugs, including Lilly's Evista (raloxifene), which began clinical trials for breast cancer but was developed for osteoporosis, Celegene's Thalomid (halidomide), which began as a treatment for nausea in pregnant women and is now on the market for the treatment of leprosy, and Pfizer/NTektar's Exubera, reformulated inhaled insulin.
The US-based global pharmaceutical company, which now owns thalidomide, sells it under the brand name Thalomid.
* DDMAC also cited Celgene for sales representative promotion of its product, Thalomid, which was approved at the time only for use in the acute treatment of the cutaneous manifestations of moderate to severe erythema nodosum leprosum (ENL) and as maintenance therapy for prevention and suppression of the cutaneous manifestations of ENL recurrences.